<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613052</url>
  </required_header>
  <id_info>
    <org_study_id>151360</org_study_id>
    <nct_id>NCT02613052</nct_id>
  </id_info>
  <brief_title>Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations</brief_title>
  <official_title>The Use of Agitated Saline, Albumin, or a Propofol-albumin Mixture for Enhanced Contrast in Bubble Studies During Transesophageal Echocardiographic Examinations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled study to determine if albumin and propofol or
      albumin only will provide superior qualitative contrast enhancement during TEE bubble studies
      compared to agitated saline. Each patient will receive three randomized bubble studies
      (agitated saline, albumin, and albumin and propofol) using 10 ml of agitated contrast agent.
      The albumin and propofol mixture will consist of 7 mL of 5% albumin plus 3 mL of propofol (10
      mg/mL). Each patient will undergo qualitative review of all 3 bubble studies by 10 different
      anesthesiologists and/or cardiologists credentialed to read echocardiographic studies at the
      time of the surgical procedure, and also with retrospective review of the echo video (~200
      studies). A bicaval view will be obtained to record a 20 beat loop for each bubble study.
      Hemodynamic variables prior to injection of contrast agent; and 30 seconds, 1 minute and 2
      minutes after injection will be monitored and recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, controlled study to determine if albumin and propofol or
      albumin only will provide superior qualitative contrast enhancement during TEE bubble studies
      compared to the current standard of care contrast agent, agitated saline. The study will take
      place in the Operating Rooms (OR) at the UCSD Sulpizio Cardiovascular Center. The TEE studies
      will be reviewed by UCSD Anesthesiology or Cardiology faculty who are credentialed to read
      and interpret echocardiographic studies.

      The study population will consist of 20 English-speaking patients and all will receive two
      doses of contrast, namely agitated albumin or propofol and albumin mixture, undergoing
      cardiac surgery who require TEE. Each patient will undergo qualitative review by 10
      anesthesiologists and/or cardiologists credentialed to read echocardiographic studies at the
      time of the surgical procedure, and also with retrospective review of the echo video. The
      multiple reviewers per patient will increase the power of the study (~200 studies). Each
      patient will receive three bubble studies using 10 ml of agitated contrast agent as named
      above. The order in which each contrast agent is utilized, as well as the experimental
      contrast agent, is randomized and the interpreting physician is blinded to this information.
      Agitated saline (AS) alone will be used as a (third dose) control for each patient, which is
      the current standard contrast agent for TEE bubble studies. The other bubble studies will use
      an experimental agitated contrast agent, either a mixture of 7 mL albumin and 3 mL propofol
      (10 mg/ml) or 10 mL albumin (human). Saline and albumin 5% are intravenous fluids FDA
      approved for the use in restoration and maintenance of circulating of blood volume. Propofol
      is FDA approved for the use in induction or maintenance of general anesthesia.

      The anesthesia care team, as per the standard care during UCSD cardiac surgical procedures,
      will place a TEE probe after induction of general anesthesia and endotracheal intubation.
      During the initial TEE exam, a bicaval view will be obtained. Both the order and type of
      experimental agitated contrast agent will be randomized and blinded to the sonographer and
      reviewer. A 20 beat loop will be recorded for each bubble study. Hemodynamic variables prior
      to injection of contrast agent; and 30 seconds, 1 minute and 2 minutes after injection are
      monitored and recorded. All recorded data will be anonymized prior to review. TEE is standard
      of care and routinely used in the care of cardiac surgery patients and is not performed
      solely for this study.

      All anesthetic, surgical and medical interventions will be chosen and carried out by the
      surgical and anesthesia teams, including those involving invasive monitor placement, fluid
      administration, ventilator management and patient positioning.

      Appropriate statistical analysis will be utilized to evaluate the difference in contrast
      enhancement in the saline only, albumin, and albumin and propofol groups.

      The results of the study will be published in the peer-reviewed medical literature.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative enhancement in right atrial opacification during intraoperative TEE bubble studies</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with qualitatively enhanced right atrial opacification with albumin or albumin and propofol mixture compared to standard of care agitated normal saline, during TEE bubble studies using the bicaval view.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Transesophageal Echocardiography Contrast Agents</condition>
  <arm_group>
    <arm_group_label>Agitated Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mL of agitated 5% albumin will be used for the bubbly study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin and Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>10 mL of normal saline agitated prior to IV administration</description>
    <arm_group_label>Agitated Normal Saline</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human albumin</intervention_name>
    <description>10 mL of 5% albumin agitated prior to IV administration</description>
    <arm_group_label>Albumin only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human albumin and propofol</intervention_name>
    <description>7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration</description>
    <arm_group_label>Albumin and Propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cardiac surgical patients requiring a transesophageal echocardiogram (TEE)

        Exclusion Criteria:

          -  allergy to propofol

          -  inability to place a TEE probe

          -  inability to obtain a TEE bicaval image

          -  known right to left intracardiac shunt

          -  pt refusal to accept human blood products including albumin

          -  pt refusal to participate in study

          -  vulnerable patients (pregnant women, prisoners, cognitively impaired, or
             institutionalized)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Swapnil Khoche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ryan YS Suda, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan YS Suda, MD</last_name>
    <email>rsuda@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Swapnil Khoche, MD</last_name>
    <email>skhoche@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego Sulpizio Cardiovascular Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan YS Suda, MD</last_name>
      <email>rsuda@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Swapnil Khoche, MD</last_name>
      <email>skhoche@ucsd.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meerbaum S. Introduction and general background. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.2</citation>
  </reference>
  <reference>
    <citation>Stewart MJ. Contrast echocardiography. Heart. 2003 Mar;89(3):342-8. Review.</citation>
    <PMID>12591856</PMID>
  </reference>
  <reference>
    <citation>Attaran RR, Ata I, Kudithipudi V, Foster L, Sorrell VL. Protocol for optimal detection and exclusion of a patent foramen ovale using transthoracic echocardiography with agitated saline microbubbles. Echocardiography. 2006 Aug;23(7):616-22.</citation>
    <PMID>16911341</PMID>
  </reference>
  <reference>
    <citation>Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. Adv Drug Deliv Rev. 2004 May 7;56(9):1291-314. Review.</citation>
    <PMID>15109770</PMID>
  </reference>
  <reference>
    <citation>Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, Burns PN, Castello R, Coon PD, Hagen ME, Jollis JG, Kimball TR, Kitzman DW, Kronzon I, Labovitz AJ, Lang RM, Mathew J, Moir WS, Nagueh SF, Pearlman AS, Perez JE, Porter TR, Rosenbloom J, Strachan GM, Thanigaraj S, Wei K, Woo A, Yu EH, Zoghbi WA; American Society of Echocardiography. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr. 2008 Nov;21(11):1179-201; quiz 1281. doi: 10.1016/j.echo.2008.09.009.</citation>
    <PMID>18992671</PMID>
  </reference>
  <reference>
    <citation>Porter TR, Abdelmoneim S, Belcik JT, McCulloch ML, Mulvagh SL, Olson JJ, Porcelli C, Tsutsui JM, Wei K. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2014 Aug;27(8):797-810. doi: 10.1016/j.echo.2014.05.011. Review.</citation>
    <PMID>25085408</PMID>
  </reference>
  <reference>
    <citation>Shapiro JR, Reisner SA, Lichtenberg GS, Meltzer RS. Intravenous contrast echocardiography with use of sonicated albumin in humans: systolic disappearance of left ventricular contrast after transpulmonary transmission. J Am Coll Cardiol. 1990 Dec;16(7):1603-7.</citation>
    <PMID>2254545</PMID>
  </reference>
  <reference>
    <citation>Davison P, Clift PF, Steeds RP. The role of echocardiography in diagnosis, monitoring closure and post-procedural assessment of patent foramen ovale. Eur J Echocardiogr. 2010 Dec;11(10):i27-34. doi: 10.1093/ejechocard/jeq120. Review.</citation>
    <PMID>21078836</PMID>
  </reference>
  <reference>
    <citation>Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005 Oct;103(4):860-76. Review.</citation>
    <PMID>16192780</PMID>
  </reference>
  <reference>
    <citation>de Jong N, Emmer M, van Wamel A, Versluis M. Ultrasonic characterization of ultrasound contrast agents. Med Biol Eng Comput. 2009 Aug;47(8):861-73. doi: 10.1007/s11517-009-0497-1. Epub 2009 May 26.</citation>
    <PMID>19468770</PMID>
  </reference>
  <reference>
    <citation>Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000 Sep 15;86(6):669-74.</citation>
    <PMID>10980221</PMID>
  </reference>
  <reference>
    <citation>Dewhirst E, et al. The Use of a Propofol-Saline Mixture for Enhanced Contrast in Bubble Studies During Echocardiographic Examinations. Society of Pediatric Anesthesia Meeting (Winter 2012).</citation>
  </reference>
  <reference>
    <citation>Geny B, Mettauer B, Muan B, Bischoff P, Epailly E, Piquard F, Eisenmann B, Haberey P. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol. 1993 Oct;22(4):1193-8.</citation>
    <PMID>8409060</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Ryan Suda</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

